The ownership structure of Barinthus Biotherapeutics (BRNS) stock is a mix of institutional, retail and individual investors. Approximately 24.32% of the company’s stock is owned by Institutional Investors, 39.51% is owned by Insiders and 36.18% is owned by Public Companies and Individual Investors.
The ownership structure of Barinthus Biotherapeutics (BRNS) stock is a mix of institutional, retail and individual investors. Approximately 24.32% of the company’s stock is owned by Institutional Investors, 39.51% is owned by Insiders and 36.18% is owned by Public Companies and Individual Investors.
Top Shareholders
Holder
# of Shares
Type
% Holding
Value
11,568
Institution
0.03%
13,766
Top Mutual Fund Holders
Holder
# of Shares
Type
% Holding
Value
11,568
Institution
0.03%
13,766
Top ETF Holders
Holder
# of Shares
Type
% Holding
Value
FAQ
Who Owns Barinthus Biotherapeutics (BRNS)?
According to the latest TipRanks data, approximately 24.29% of the company's stock is held by institutional investors, 39.51% is held by insiders, and 36.18% is held by retail investors.
What percentage of Barinthus Biotherapeutics (BRNS) stock is held by institutional investors?
According to the latest TipRanks data, approximately 24.29% of Barinthus Biotherapeutics (BRNS) stock is held by institutional investors.
What percentage of Barinthus Biotherapeutics (BRNS) stock is held by retail investors?
According to the latest TipRanks data, approximately 36.18% of Barinthus Biotherapeutics (BRNS) stock is held by retail investors.
Who owns the most shares of Barinthus Biotherapeutics (BRNS)?
Fidelity Concord Street Trust owns the most shares of Barinthus Biotherapeutics (BRNS).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.